| ADFS | alternative delivery and financing system |
|---|---|
| BHCDA | Bureau of Health Care Delivery and Assistance |
| CTVDR | conformal treatment verification, delivery and recording [system] |
| LD | labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear... |
| L&D | labor and delivery |
| CALLA | common ALL antigen |
|---|---|
| ACCESS | Access to Community Care and Effective Services and Support |
| EPSDT | Early and Periodic Screening Diagnosis and Treatment |
| SUPPORT | Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment |
| AMBER | Advanced Multiple Beam Equalization Radiography |
one and one-half syndrome
| miscarriages, multiple, chromosomes in | Couples who have had more than one miscarriage have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages. (12 Dec 1998) |
|---|---|
| multiple | Manifold, occurring in or affecting various parts of the body at once. Origin: L. Multiplex (18 Nov 1997) |
| multiple alcohol | An alcohol containing more than one OH group. (05 Mar 2000) |
| multiple amputation | Amputation of two or more limbs or parts of limbs performed at the same operation. (05 Mar 2000) |
| multiple anchorage | Anchorage in which more than one type of resistance unit is utilised. Synonym: reinforced anchorage. (05 Mar 2000) |
| multiple birth offspring | The offspring in multiple pregnancies (pregnancy, multiple): twins, triplets, quadruplets, quintuplets, etc. (12 Dec 1998) |
| multiple carboxylase deficiency | Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase. (12 Dec 1998) |
| multiple chemical sensitivity | An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61) (12 Dec 1998) |
| multiple cloning site | Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments. (18 Nov 1997) |
| multiple drug resistant tuberculosis | A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance. (09 Oct 1997) |
| multiple ego states | Various psychological organizational state's reflecting different personas or life experiences. (05 Mar 2000) |
| multiple embolism | Embolism caused by the arrest of a number of small emboli. (05 Mar 2000) |
| multiple endocrine adenomatosis | The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance. Synonym: multiple endocrine adenomatosis. (05 Mar 2000) |
| multiple endocrine deficiency syndrome | <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis. Synonym: multiple glandular deficiency syndrome. (05 Mar 2000) |
| multiple endocrine neoplasia | (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour. (type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor. Incidence: approximately 3 in 100,000 people in the general population. Origin: Gr. Plassein = to form (27 Sep 1997) |